Third-line therapy for chronic myeloid leukemia: current status and future directions

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optimal target for tyrosine kinase inhibitors (TKIs) that aim for the adenosine triphosphate (AT...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge, Lang, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976694/
https://www.ncbi.nlm.nih.gov/pubmed/33736651
http://dx.doi.org/10.1186/s13045-021-01055-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976694/
https://www.ncbi.nlm.nih.gov/pubmed/33736651
http://dx.doi.org/10.1186/s13045-021-01055-9

Ejemplares similares